OBJECTIVES: The only locus unequivocally associated with late onset Alzheimer's disease (AD) risk is APOE. However, this locus accounts for less than half the genetic variance. A recent study suggested that the A allele of the 3'UTR biallelic polymorphism in the LBP-1c/CP2/LSF gene was associated with reduced AD risk. Samples were diagnosed predominantly by clinical rather than pathological criteria. We have sought to replicate this finding in a series of necropsy confirmed, late onset AD cases and non-demented controls. METHODS: The 3'UTR polymorphism in the LBP-1c/CP2/LSF gene was typed in 216 necropsy confirmed AD cases and 301 non-demented controls aged >73 years. RESULTS: We found different LBP-1c/CP2/LSF allele distributions in our AD cases and controls (p=0.048); the A allele was associated with reduced AD risk. The allele and genotype frequencies observed in our cases and controls were similar to those previously reported. No significant effects emerged when the data were adjusted for age, sex, or apoE epsilon4 carrier status. CONCLUSIONS: Our data support LBP-1c/CP2/LSF as a candidate gene/risk factor for AD and provide justification for future studies to investigate the role of this gene in Alzheimer's disease.
OBJECTIVES: The only locus unequivocally associated with late onset Alzheimer's disease (AD) risk is APOE. However, this locus accounts for less than half the genetic variance. A recent study suggested that the A allele of the 3'UTR biallelic polymorphism in the LBP-1c/CP2/LSF gene was associated with reduced AD risk. Samples were diagnosed predominantly by clinical rather than pathological criteria. We have sought to replicate this finding in a series of necropsy confirmed, late onset AD cases and non-demented controls. METHODS: The 3'UTR polymorphism in the LBP-1c/CP2/LSF gene was typed in 216 necropsy confirmed AD cases and 301 non-demented controls aged >73 years. RESULTS: We found different LBP-1c/CP2/LSF allele distributions in our AD cases and controls (p=0.048); the A allele was associated with reduced AD risk. The allele and genotype frequencies observed in our cases and controls were similar to those previously reported. No significant effects emerged when the data were adjusted for age, sex, or apoE epsilon4 carrier status. CONCLUSIONS: Our data support LBP-1c/CP2/LSF as a candidate gene/risk factor for AD and provide justification for future studies to investigate the role of this gene in Alzheimer's disease.
Authors: Y Narain; A Yip; T Murphy; C Brayne; D Easton; J G Evans; J Xuereb; N Cairns; M M Esiri; R A Furlong; D C Rubinsztein Journal: J Med Genet Date: 2000-09 Impact factor: 6.318
Authors: J C Lambert; L Goumidi; F W Vrièze; B Frigard; J M Harris; A Cummings; J Coates; F Pasquier; D Cottel; M Gaillac; D St Clair; D M Mann; J Hardy; C L Lendon; P Amouyel; M C Chartier-Harlin Journal: Hum Mol Genet Date: 2000-09-22 Impact factor: 6.150
Authors: E S Paykel; C Brayne; F A Huppert; C Gill; C Barkley; E Gehlhaar; L Beardsall; D M Girling; P Pollitt; D O'Connor Journal: Arch Gen Psychiatry Date: 1994-04
Authors: L A Farrer; L A Cupples; J L Haines; B Hyman; W A Kukull; R Mayeux; R H Myers; M A Pericak-Vance; N Risch; C M van Duijn Journal: JAMA Date: 1997 Oct 22-29 Impact factor: 56.272
Authors: Prasanna K Santhekadur; Devaraja Rajasekaran; Ayesha Siddiq; Rachel Gredler; Dong Chen; Scott E Schaus; Ulla Hansen; Paul B Fisher; Devanand Sarkar Journal: Am J Cancer Res Date: 2012-04-21 Impact factor: 6.166
Authors: J-C Lambert; E Luedecking-Zimmer; S Merrot; A Hayes; U Thaker; P Desai; A Houzet; X Hermant; D Cottel; A Pritchard; T Iwatsubo; F Pasquier; B Frigard; P M Conneally; M-C Chartier-Harlin; S T DeKosky; C Lendon; D Mann; M I Kamboh; P Amouyel Journal: J Med Genet Date: 2003-06 Impact factor: 6.318
Authors: Miguel Verbitsky; Amanda L Yonan; Gaël Malleret; Eric R Kandel; T Conrad Gilliam; Paul Pavlidis Journal: Learn Mem Date: 2004 May-Jun Impact factor: 2.460